Search

everythinglearnresearchcommunity

for

Search:↓

Mefloquine, an antimalarial drug, is effective in killing melanoma cells resistant to other treatments by causing lethal stress in the cells.

Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.

MK-5108 is safe and shows potential against tumors, especially alone.

Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.

Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.

Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.

Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.

Pemigatinib may be effective for treating ZMYM2::FGFR1 fusion-positive leukemia.

Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.

Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.

Ritlecitinib is effective and safe for hair regrowth in Asian patients with alopecia areata.

Tofacitinib helped regrow hair in patients with alopecia, with few side effects.

Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.

Ruxolitinib helped a woman with a genetic mutation regrow her hair and improved her health.

A Korean woman with complete hair loss regrew her hair after taking tofacitinib, with no side effects.

Tyrosine kinase inhibitors for endocrine tumors often cause skin issues, requiring early management and treatment adjustments.

Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.

Sorafenib can cause a temporary skin condition that goes away after stopping the drug.

Gefitinib can cause hair and eyebrow darkening.

Clinicians should consider individual factors and communicate risks and benefits when prescribing ritlecitinib for adolescent alopecia areata.

Ritlecitinib improves hair regrowth in alopecia areata without increasing adverse risks.

New melanoma treatments can cause skin side effects, including skin cancer and rashes, but combining treatments may reduce these risks.

Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.

Tofacitinib helped most teenagers in the study regrow hair with mild side effects.

Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.

Gefitinib treatment led to unexpected hair growth in two lung cancer patients.

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.

Tofacitinib effectively treated severe hair loss in a patient who didn't respond to other treatments.

Tofacitinib may effectively treat skin symptoms in difficult cases of dermatomyositis.